.
The endogenous chemical mediators that are intentionally released by cells that infiltrate the site of challenge include the eicosanoids (such as prostaglandin E 2 and leukotriene B 4 ) and complement components (such as C5a), which are important for host defence, but which can also lead inadvertently to tissue damage. Endogenous chemical mediators are released during sterile injury, such as in ischaemia-reperfusion injury 3 . This route of chemical mediator release can be amplified by overt activation and excessive recruitment of neutrophils to the site of injury that sustain the inflammatory response by further spilling of noxious granule contents and by the generation of other chemical mediators (FIG. 1) .
Acute inflammation has several programmed fates including progression to chronic tissue fibrosis and the ideal outcome of complete resolution 1 . Challenges are met by infiltrating phagocytic cells of the innate immune system, primarily neutrophils, which traffic by sensing gradients of chemoattractants from postcapillary venules to the tissue via diapedesis (FIG. 1) . These chemoattractants consist of endogenous lipid mediators, such as leukotrienes, and protein mediators, including chemokines and cytokines 4 , as well as exogenous chemoattractants released, for example, by microorganisms. Time-dependent progression of cell infiltration is led by specific leukocyte subtypes, namely, professional phagocytes, with neutrophils being the first to enter, followed by monocytes 5 .
Once the initiating noxious materials are removed via phagocytosis, the inflammatory reaction must be resolved to prevent the inflammation from spreading, becoming chronic or causing disease. Resolution of inflammation, or its catabasis 6 , is the reduction or removal of leukocytes 
Ischaemia-reperfusion injury
An injury in which the tissue first suffers from hypoxia as a result of severely decreased, or completely arrested, blood flow. Restoration of normal blood flow then triggers inflammation, which exacerbates the tissue damage.
and debris from inflamed sites, enabling the return to homeostasis. The resolution of inflammatory leukocytic infiltrates was previously considered to be a passive process 7 . local chemotactic stimuli and gradients, for example, were thought to dissipate or simply 'burn out' with time, enabling tissues to drain, repair and return to normal function 1 . As we review here, recent findings indicate that resolution is not merely a passive termination initiates the release of exogenous chemoattractants (such as microbial peptides and endotoxins) and endogenous chemical mediators that can activate leukocyte recruitment and antimicrobial activities. Microorganisms taken up by phagocytosis activate bacterial killing mechanisms in, for example, neutrophil phagolysosomal vacuoles. Sometimes, during incomplete phagocytosis, neutrophil phagolysosomal vacuole contents (such as reactive oxygen species (ROS) and hydrolytic enzymes) can inadvertently spill into the extracellular milieu, and this leads to local tissue damage and/or unwanted amplification of pro-inflammatory responses. Surgical trauma and ischaemia-reperfusion injury also activate the release of endogenous chemical mediators, such as leukotriene B 4 , prostaglandin E 2 and C5a. These mediators and others are involved in the development of the cardinal signs of acute inflammation, which involve vasoconstriction, vasodilation, vascular permeability and chemotaxis. The outcome of acute inflammation -resolution, chronicity and fibrosis -may be influenced by many factors, such as the type or site of injury, and the host response. The reestablishment of normal homeostasis (resolution) is an actively regulated programme. Prostaglandin E 2 and prostaglandin D 2 , for example, stimulate the switching of arachidonic-acid-derived lipids from leukotriene B 4 production to lipoxin A 4 production and then the switching of lipid mediator families to produce anti-inflammatory and pro-resolution lipid mediators, such as E-series and D-series resolvins and protectins. Alternatively, chronic inflammation can result from excessive and/or unresolved inflammatory responses and can lead to chronic disorders. Arachidonic-acid-derived lipid mediators such as pro-inflammatory prostaglandins and leukotrienes can amplify this process. Fibrosis can occur when inflammatory injury causes substantial tissue destruction, connective tissue replacement occurs and results in loss of tissue function. b | Both exogenous and endogenous chemoattractant gradients stimulate the recruitment of neutrophils via diapedesis from postcapillary venules, an event that is amplified by the production of local leukotriene B 4 . During the tissue progression of inflammatory events, intravascular platelet-leukocyte interactions induce the formation of lipoxin A 4 and lipoxin B 4 , which stop further recruitment of neutrophils and stimulate non-phlogistic monocyte infiltration. c | The chemical structures of pro-resolution mediators lipoxin A 4 , resolvin E1, resolvin D1 and protectin D1 are shown.
Diapedesis
The migration of leukocytes across the endothelium, which occurs by squeezing through the junctions between adjacent endothelial cells. This is the last step in the leukocyteendothelial-cell adhesion cascade that includes tethering, triggering, tight adhesion and transmigration.
Leukotrienes
A class of eicosanoids derived from the metabolism of arachidonic acid by the action of leukocyte 5-lipoxygenase and other enzymes. They have a conjugated triene doublebond structure and various pro-inflammatory activities, including leukocyte activation (by leukotriene B 4 ) and bronchoconstriction (by leukotriene C 4 and leukotriene D 4 ).
Lipoxins
A class of eicosanoids that are produced by lipoxygenasemediated metabolism of arachidonic acid. They are trihydroxytetraene-containing structures with potent biological activities in the resolution of inflammation.
Resolvins
Lipid mediators that are induced in the resolution phase following acute inflammation. They are synthesized from the essential omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Protectins
A family of docosahexaenoic acid (DHA)-derived mediators characterized by the presence of a conjugated triene doublebond structure and 22 carbons with 6 double bonds. of inflammation, but rather an active biochemical and metabolic process 6, 7 . The resolution process is rapidly initiated after acute challenges by cellular pathways that actively biosynthesize local, specialized, dual-acting antiinflammatory and pro-resolution lipid mediators, such as the lipoxins, resolvins and protectins 8, 9 (FIG. 1) .
in this Review, we provide an update and overview of newly identified lipid mediators that have pivotal roles in the resolution of inflammation and in disease models. unexpectedly, two of these recently described lipid mediator families, the resolvins and protectins, are biosynthesized from precursor essential omega-3 polyunsaturated fatty acids (PuFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [9] [10] [11] 
.
Resolution of inflammation: new concepts
The resolution of inflammation was defined in modern molecular terms relatively recently 6, 8, 12, 13 . importantly, it is now considered to be a distinct process from antiinflammatory processes 5 . This is because, in addition to serving as agonists to stop and reduce neutrophil infiltration to inflamed tissues, pro-resolution molecules promote the uptake and clearance of apoptotic cells and microorganisms by macrophages in inflamed sites 14, 15 (FIG. 2) , and stimulate the antimicrobial activities of mucosal epithelial cells 16, 17 . The resolution of inflammation is accompanied by an active switch in the mediators that predominate in exudates. initially, mediators, such as classic prostaglandins and leukotrienes, which activate and amplify the cardinal signs of inflammation, are generated. next, prostaglandin E 2 and prostaglandin D 2 , by inducing the production of key enzymes, gradually promote the synthesis of mediators that have both anti-inflammatory and proresolution activities, such as the lipoxins 8, 14 , resolvins and protectins [9] [10] [11] (FIG. 1) . These families of endogenous pro-resolution molecules are not immunosuppressive, but instead function in the resolution of inflammation by activating specific mechanisms to promote homeostasis. in general, pro-resolution molecules stimulate and accelerate resolution via mechanisms at the tissue level that are multi-factorial (FIG. 2) . Specific lipoxins and members of the resolvin and protectin families provide potent signals that selectively stop neutrophil and eosinophil infiltration; stimulate non-phlogistic recruitment of monocytes (that is, without elaborating pro-inflammatory mediators); activate macrophage phagocytosis of microorganisms and apoptotic cells; increase the exit of phagocytes from the inflamed site through the lymphatics; and stimulate the expression of molecules involved in antimicrobial defence 5, 10, 16, 17 . lipid mediators, such as prostaglandins and leukotrienes, are widely appreciated for their pro-inflammatory activities 18, 19 . using either cyclooxygenases or lipoxygenases, leukocytes rapidly biosynthesize these lipid mediators from membrane-derived arachidonic acid within seconds to minutes of acute challenge. Recent results, however, indicate that as inflammation proceeds the neutrophils in confined exudates stop producing chemoattractants (such as leukotriene B 4 ) and within hours begin to convert arachidonic acid into protective lipoxins, thereby serving as agonists to actively terminate inflammation and promote resolution [7] [8] [9] . in contained exudates in certain inflamed tissues and inflammatory diseases 1, 20, 21 , both prostaglandin E 2 and prostaglandin D 2 have pro-inflammatory activities 18 , but each can promote a switch in the expression of biosynthetic enzymes by infiltrating neutrophils that changes their phenotype to a pro-resolution phenotype -a process known as lipid-mediator class switching 8 . it is worth noting that, in certain settings in which prostaglandin E 2 is delivered pharmacologically, it can have anti-inflammatory activities, through the stimulation of cyclic AmP 22 . Therefore, in these settings, prostaglandin E 2 is not acting as a pro-resolution mediator by definition 23 because it does not stimulate the nonphlogistic responses of macrophages, namely, the uptake and clearance of apoptotic cells. in addition, in the presence of leukotriene B 4 or C5a, prostaglandin E 2 can enhance inflammation 24 . Prostaglandin D 2 can also increase intracellular cyclic AmP levels in certain cell types and have anti-inflammatory actions 25 , whereas its non-enzymatic degradation products (that is, 15-deoxy-delta-12,14-prostaglandin J 2 and related cyclopentaenones) can enhance resolution by promoting leukocyte apoptosis and macrophage clearance from inflamed sites 26 , possibly by inhibiting nuclear factor-κB (nF-κB) activation 27 .
Lipoxins: anti-inflammatory and pro-resolving Production of lipoxins. lipoxins were the first mediators recognized to have dual anti-inflammatory and pro-resolution activities 14, 28 . . This activity is enhanced during inflammation but is also likely to provide a mechanism for restoring homeostasis, because mucosal surfaces are continuously exposed to microorganisms in vivo [29] [30] [31] . in the mucosa, lipoxins are generated by neutrophils from the 15-hydroxyeicosatetraenoic acid (15-HETE) precursor, which is provided by mucosal epithelial cells 29 . The blood vessels represent another main site where lipoxin biosynthesis occurs in humans; biosynthesis involves the initiation of arachidonic-acid oxygenation by 5-lipoxygenase in leukocytes and the release of the intermediate leukotriene A 4 , which is converted by the lipoxinsynthase activity of 12-lipoxygenase in platelets. This biosynthesis pathway is exemplified by platelet-leukocyte interactions in blood vessels or possibly in exudates that form a nidus for transcellular biosynthesis.
in inflamed sites, neutrophils can interact with other cells in their immediate vicinity, such as with other leukocytes, platelets, endothelial cells, mucosal epithelial cells and fibroblasts, and acquire the ability to produce lipoxins. more than 50% of the leukocyte-derived epoxide intermediate leukotriene A 4 is released by cells for processing by platelet 12-lipoxygenase or mucosal 15-lipoxygenase to produce lipoxins [32] [33] [34] . lipoxins generated by cell-cell interactions and transcellular biosynthesis stop neutrophil diapedesis and recruitment into the tissues [29] [30] [31] (FIG. 1) .
it is now clear that neutrophils change their phenotype to produce different profiles of lipid mediators depending on the cells and substrates present in their local environment 8, 9 . For example, neutrophils in resolving inflammatory exudates switch from the production of leukotrienes to that of lipoxins and resolvins, whereas neutrophils in the peripheral blood, on activation, generate and release leukotriene B 4 as one of their main bioactive products 8 . in this context, local prostaglandin E 2 and prostaglandin D 2 stimulate the processing of 15-lipoxygenase mRnA in leukocytes to produce a functional enzyme for lipoxin production 8 . Other cell types can acquire the ability to generate lipoxins when exposed to specific cytokines or growth factors 32 , or in the case of macrophages, for example, when they engulf apoptotic leukocytes 35 . These findings are of relevance to pro-resolution mechanisms because lipoxin A 4 generated by macrophages probably contributes to the stimulation of their phagocytic activity 15, 17 without elaborating pro-inflammatory mediators -namely, the non-phlogistic process.
Pathogens can also contribute to the provision of the necessary components for lipoxin biosynthesis. Pseudomonas aeruginosa encodes the first identified secretory lipoxygenase that converts host arachidonic acid to 15-HETE for local lipoxin production 36 . High levels of lipoxins, greater than those considered to be physiologically standard, are produced by host cells infected by Toxoplasma gondii, which encode their own 15-lipoxygenase 37, 38 . Therefore, 15-lipoxygenase expressed by pathogens may interact with endogenous biosynthetic circuits of the host to generate local 'stop signals' at levels that can divert the host immune defence.
Pro-resolution actions of lipoxins. lipoxin A 4 and lipoxin B 4 inhibit neutrophil entry into inflamed sites and counter-regulate the main aspects of inflammation. They act on many cell types including blood cells, neural cells and stromal cells [39] [40] [41] [42] (TABLE 1) . lipoxin A 4 regulates leukocyte responses in vitro and trafficking in vivo by activating its specific receptor, lipoxin A 4 receptor (AlX) (FIG. 3) . AlX is a G-protein-coupled receptor (GPCR) that is expressed by leukocytes and has cell-type-specific signalling pathways 40 . For example, in neutrophils, lipoxin-A 4 -AlX interactions stop neutrophil migration, whereas in monocytes lipoxin-A 4 -AlX interactions stimulate monocyte chemotaxis and non-phlogistic responses 41 . unlike classic GPCRs for chemoattractants that mobilize intracellular Ca 2+ to evoke chemotaxis, lipoxins instead induce changes in the phosphorylation of proteins of the cytoskeleton, resulting in cell arrest 42, 43 . in addition to these effects on the resolution of inflammation, lipoxin A 4 reduces organ fibrosis, acts directly on both vascular and smooth muscle (for reviews, see REFs 14, 40) and has direct action in reducing pain 44 . Aspirin impinges the endogenous lipoxin-generating system during cell-cell interactions. inhibition of prostaglandin biosynthesis by aspirin is a well-appreciated mechanism in its anti-thrombotic and anti-inflammatory effect 45 . Of interest, aspirin triggers the endogenous formation of carbon-15 epimeric lipoxins, namely aspirin-triggered lipoxins (ATls) 46 . Cells that express cyclooxygenase-2 (COX2), including vascular endothelial cells, epithelial cells, macrophages and neutrophils, are involved in ATl production. Acetylation of COX2 by aspirin blocks its ability to biosynthesize prostaglandins The key histological feature in the resolution of inflammation is the loss of neutrophils from the local inflamed sites. This is a programmed process that is actively regulated at multiple levels: by reducing neutrophil infiltration into the exudate, increasing monocyte recruitment to the exudate, stimulating macrophage uptake of apoptotic neutrophils, and promoting phagocyte exit from the exudate via the lymphatics.
but does not impair its ability to produce ATl precursors. Accordingly, the production of ATls is increased in aspirin-treated animals compared with control animals, and importantly in healthy humans taking low doses of aspirin 
Statins
A class of drugs that inhibit the rate-limiting enzyme (3-hydroxy-3-methylglutaryl coenzyme A reductase) in the pathway of cholesterol biosynthesis. These molecules are mainly used as cholesterollowering drugs, but they also have immunoregulatory and anti-inflammatory properties.
Murine dorsal air pouch model
A well-characterized model for studying inflammatory responses. Air pouches are formed by subcutaneous injection of air into the back of a mouse, into which potential inflammatory stimuli, such as tumour-necrosis factor, can be added. Importantly, when the stimulus is titrated, inflammatory reactions undergo spontaneous resolution. These structurally contained compartments have been likened to the inflamed synovium.
Compelling findings in experimental animal systems that demonstrate both the anti-inflammatory and proresolution actions of lipoxins and ATls in vivo (TABLE 2) have established that preventative treatment with a proresolution mediator reduces inflammation and disease status 15, 51 . Therefore, endogenous ATls (15-epi-lipoxins) offer new and potentially important mechanisms that underlie the clinical benefits of aspirin [47] [48] [49] [50] . 15-epi-lipoxin production may also be an essential mechanism of other widely used drugs, such as statins, which stimulate the production of endogenous 15-epi-lipoxin A 4 (REF. 52 ).
Of interest, both lipoxins and ATls directly act on human T cells 53 to block secretion of tumour-necrosis factor (TnF). Human peripheral T cells express AlX, and activation of this receptor blocks CD3-specificantibody-induced activation of extracellular signal-regulated kinase (ERK), which is required for TnF secretion. 
Resolvins and protectins
Previous studies have shown that essential omega-3 PuFAs administered at daily high doses (milligrams to grams) have beneficial actions in many inflammatory diseases, cancer and human health in general 20, 55, 56 . However, the molecular basis of omega-3 fatty acid action was not established until recently. To identify potential mechanisms that are actively involved in the resolution of inflammation, we devised a new lipid-mediator approach based on lipidomics 9,10 and informatics 57 , with liquid chromatography-ultraviolet-tandem massspectrometry-based analyses, to map and profile the appearance and/or loss of mediators in resolving inflammatory exudates. When novel bioactive compounds were encountered, their structures were elucidated and their bioactivity and role(s) confirmed in vivo [9] [10] [11] 51, 58 . These studies uncovered two new families of bioactive mediators -termed resolvins and protectins -that are biosynthesized from omega-3 essential PuFAs.
Resolvins. The first resolvin was identified in exudates 9 collected from inflamed murine dorsal air pouches in the spontaneous resolution phase 59 , and was so-named because it proved to be a potent regulator of resolution. Resolvins are derived from EPA and DHA with two chemically unique structural forms, the E-series and D-series, respectively. E-series member resolvin E1 reduces inflammation in vivo and blocks human neutrophil transendothelial migration 9 . Resolvin E1 can be produced in vitro, recapitulating events in vivo, by treating human vascular endothelial cells in a hypoxic environment with aspirin. These cells convert EPA to 18R-hydroperoxyeicosapentaenoic acid (18R-HPEPE) and release 18R-hydroxyeicosapentaenoic acid (18R-HEPE), which is rapidly transformed by activated human neutrophil 5-lipoxygenase 9, 60 . Resolvin E1 is produced in healthy individuals and is increased in the plasma of individuals taking aspirin and/or EPA 58 . Resolvin E2 is the second E-series member that reduces zymosan-initiated neutrophil infiltration, thereby displaying potent anti-inflammatory actions 60 . These EPAderived E-series resolvins might contribute to the beneficial actions that have been attributed to omega-3 PuFAs in human diseases, such as skin inflammation, peritonitis 9 , periodontal disease 23, 61 and colitis 62 (TABLE 2) . indeed, the production of 5-lipoxygenase in human leukocytes is pivotal for these beneficial effects and is controlled in part by temporal and spatial events in vivo to signal the production of either leukotrienes or anti-inflammatory mediators, such as lipoxins and resolvins. Of interest, microbial and mammalian cytochrome P450 enzymes convert EPA into 18-HEPE 9 , which can be transformed by human neutrophils to resolvin E1 and resolvin E2. Hence, it is likely that microorganisms at sites of inflammation or in the gastrointestinal tract can contribute to the production of E-series resolvins in humans.
Two receptors are known to be involved in the actions of resolvin E1 (FIG. 3) . The GPCR chemokine-like receptor 1 (CmKlR1; also known as ChemR23) attenuates TnFstimulated nF-κB activation in response to resolvin E1 binding, indicating a counter-regulatory action of this ligand-receptor pair 58 . Counter-regulation of TnF signalling was used to identify this GPCR because TnF is a key mediator in the early steps of acute inflammation 9, 58 . Recently, a second GPCR that interacts with resolvin E1 was identified, the leukotriene B 4 receptor (BlT1) 63 . Resolvin E1 interacts in a stereospecific manner with BlT1 expressed by human neutrophils as a receptor antagonist 9 , attenuating leukotriene-B 4 -dependent proinflammatory signals via BlT1 (REF. 63 ). Accordingly, the antiinflammatory actions of resolvin E1 are markedly reduced in BlT1-deficient mice. So, to counter-regulate inflammation and promote resolution, resolvin E1 selectively interacts with at least two GPCRs present on different cell types, namely CmKlR1 on monocytes and dendritic cells, and BlT1 on neutrophils.
DHA is the substrate for two groups of resolvins produced by different biosynthetic routes, referred to as the 17S and 17R D-series resolvins, during the resolution of inflammatory exudates 10, 11 . D-series resolvins display potent anti-inflammatory actions 10 and are particularly interesting because the brain, synapses and retina are highly enriched in DHA [64] [65] [66] . Endogenous DHA is converted in vivo via lipoxygenase-initiated mechanisms to the 17S-hydroxy-containing series of four resolvins, known as resolvin D1-resolvin D4 (REFs 10,11). Each of these potent bioactive resolvins was first isolated in exudates from mice that had been given aspirin and DHA; this led to the identification of several new 17R-hydroxycontaining products in exudates during the resolution phase 10 . Their ability to stop neutrophil infiltration was used to assess their biological function for structural elucidation studies 10 and their biosynthesis was reconstructed to establish their potential origins. Results from these studies showed that human recombinant COX2 converts DHA into a 13-hydro(peroxy)-containing product. in the presence of aspirin, the oxygen at carbon position 13 switches to position 17 with an R configuration that is a precursor for the aspirin-triggered 17R D-series resolvins. These are produced in exudates and in the brain in response to aspirin treatment 10, 11 . Resolvin D1 and aspirin-triggered resolvin D1 are both potent regulators of human and mouse neutrophils 10,67 (TABLE 1) . in microglial cells, both the 17S and 17R D-series resolvins block the production of TnF-induced transcripts that encode the pro-inflammatory cytokine interleukin-1β (il-1β), which is expressed rapidly in response to neural injury 11, 68 . Resolvins control inflammation at many levels, by reducing peritonitis and skin inflammation 10,11 , protecting organs from reperfusion injury and neovascularization (TABLE 2) . Therefore, the D-series resolvins are of interest in the control of inflammation resolution in host defence and in neural tissues.
Protectins. DHA in resolving exudates is converted to another molecule belonging to a new family of mediators named protectins. Protectins are distinguished by the presence of a conjugated triene double bond and by their potent bioactivity 10,11 . They are biosynthesized via a lipoxygenase-mediated pathway that converts DHA to a 17S-hydroperoxide-containing intermediate 11 , which is rapidly converted by human leukocytes into a 16(17)-epoxide that is enzymatically opened in these cells into a 10,17-dihydroxy-containing anti-inflammatory molecule 10, 11 . This bioactive compound, initially referred to as 10,17-diHDHA or 10,17S-docosatriene 11 , is now known as protectin D1, owing to its potent protective activity in inflammatory 51 and neural systems that has been documented in studies by Bazan and colleagues 66, 69, 70 . When produced by neural tissues, it is termed neuroprotectin D1 (REF. 70) ; the prefix neuro is added to depict its biosynthetic origin 51 . Several 10,17-dihydroxy-containing products are produced in vivo via different biosynthetic routes, the most potent of these products being protectin D1. The other natural protectin D1 isomers have different double-bond configurations and are less potent in dampening neutrophil recruitment and inflammation 51 . Protectin D1 is stereoselective and is log-orders of magnitude more potent in vivo than its precursor DHA. Protectin D1 is also produced by human peripheral blood mononuclear cells in T-helper-2-type conditions in a lipoxygenase-dependent manner via a 16 (17) T max = ∼12 hr T 50 = ∼24 hr
Alzheimer's disease A degenerative neurological disease that is characterized by progressive deterioration of the brain, dementia, and the presence of senile plaques, neurofibrillary tangles and neuropil threads. Disease onset can occur at any age, and women seem to be affected more frequently than men.
Agonists of inflammation resolution. Specific resolvins, protectins and lipoxins stereoselectively stimulate resolution and reduce the magnitude of the inflammatory response in vivo (TABLEs 1,2) . The clearance of apoptotic neutrophils by professional phagocytes, such as macrophages, is a cellular hallmark of inflammatory tissue resolution 72 , and this can be used to quantify resolution using specific indices 6 (FIG. 4) . Resolvin E1 initiates resolution of inflammation and causes a decrease in the number of neutrophils in exudates at earlier times than does spontaneous resolution. Protectin D1 shifts the onset of resolution to an earlier time point and in addition shortens the time taken to reduce the number of maximum neutrophils by half as indicated by the calculation of the resolution interval (FIG. 4) . The pro-resolution actions of both resolvin E1 and protectin D1 are achieved by reducing neutrophil influx and stimulating macrophage ingestion of apoptotic neutrophils, as well as by enhancing the number of phagocytes present in the lymph nodes and spleen 15 .
Disruption of biosynthesis of these pro-resolution mediators by either COX2 or lipoxygenase inhibitors gives rise to a 'resolution deficit' phenotype, which is characterized by impaired phagocytic removal, delayed resolution and prolonged inflammation. These findings emphasize a pivotal homeostatic function for lipoxygenase(s) and COX2 pathways in the timely resolution of acute inflammation. more importantly, pro-resolution mediators at lower doses than inhibitors of COX2 and lipoxygenase can rescue the deficit in resolution caused by these interventions 15 . Resolvin E1 and protectin D1 upregulate the expression of CC-chemokine receptor 5 (CCR5) by dying neutrophils 73 . CCR5 expression on late apoptotic neutrophils acts as a 'terminator' of chemokine signalling, by clearing the pro-inflammatory ligands of CCR5 (CCl3 and CCl5) from the inflammatory site. Resolvin E1, in keeping with a role in stimulating the clearance of inflammatory cells and the return to tissue homeostasis, selectively induces the expression of the anti-adhesion molecule CD55 on the apical surface of mucosal epithelial cells, and thereby promotes CD55-dependent clearance of neutrophils across mucosal surfaces 17 . So, these EPA-and DHA-derived mediators are potent resolution agonists that activate cell-typespecific programmes in, for example, neutrophils, macrophages and epithelial cells (TABLE 1) at multiple levels to accelerate resolution.
Resolution of inflammation in disease models
uncontrolled inflammation is now appreciated in the pathogenesis of many diseases that were not previously considered classic inflammatory diseases. These include atherosclerosis, cancer, asthma and several neurological disorders, such as Alzheimer's disease and Parkinson's disease. natural pro-resolution mechanisms involving lipoxins, resolvins and protectins were tested for their ability to promote resolution and control inflammation (TABLE 2) . it is now clear that endogenous anti-inflammation alone is not an identical mechanism of action compared with that of mediators that possess dual anti-inflammatory and pro-resolution actions 5 . in this regard, lipoxins, resolvins and protectins have potent multi-level mechanisms of action in disease models and promote resolution in animal models of oral, lung, ocular, kidney, skin and gastrointestinal inflammation, as well as in ischaemia-reperfusion injury and angiogenesis (TABLE 2) .
Inflammatory diseases.
Periodontal diseases, such as gingivitis and periodontitis, are leukocyte-driven inflammatory diseases characterized by soft-tissue and osteoclast-mediated bone loss 21 . As a model of inflammatory diseases, periodontitis has several advantages in that many, if not all, of the tissues involved in inflammatory processes of other organ systems are affected, including the epithelium, connective tissue and bone. indeed, there are many noteworthy similarities in the pathogenesis of periodontitis and arthritis.
Results from rabbit models of periodontitis demonstrate an important role for resolution of inflammation in 
Rabbit model of periodontitis
A model of periodontitis in rabbits induced by application of Porphyromonas gingivalis to ligatures tied to second premolars.
Alveolar bone
The thickened ridge of bone that forms the tooth socket surrounding the roots of teeth.
Ulcerative colitis
An inflammatory bowel disease characterized by chronic inflammation of the colon.
Age-related macular degeneration
A condition predominantly found in elderly adults in which the centre of the inner lining of the eye, known as the macula area of the retina, suffers thinning, atrophy and in some cases bleeding, and can result in loss of central vision. disease prevention. Overexpression of 15-lipoxygenase type i in transgenic rabbits increases the levels of endogenous lipoxin A 4 , protects against periodontitis, and reduces atherosclerosis 74, 75 . in prevention studies using this model, topical treatment with resolvin E1 prevents >95% of alveolar bone destruction. Histological analysis of rabbits treated with resolvin E1 revealed few, if any, neutrophils in the tissue and little tissue damage. in addition, osteoclasts, which are cells responsible for bone resorption, were reduced in these rabbits 61 . in established disease, resolvin E1 prevents periodontitis tissue destruction; both soft tissue and bone that were lost during disease were regenerated 23 . in humans, the differential actions of resolvin E1 were studied using neutrophils from patients with localized aggressive periodontitis (lAP) and healthy individuals. Resolvin E1 reduces neutrophil superoxide generation in response to TnF or the bacterial surrogate peptide N-formyl-methionyl-leucyl-phenylalanine. neutrophils from both healthy subjects and lAP patients produced ~80% less superoxide when treated with resolvin E1. in comparison, neutrophils from lAP patients do not exhibit inhibition of superoxide production following treatment with lipoxin A 4 , suggesting a molecular basis for excessive inflammation in these patients.
in murine dorsal air pouches, nanogram amounts of resolvin E1 (~100 nm) reduce leukocyte infiltration by 50-70%; these levels are comparable to those achieved by administering microgram amounts of dexamethasone (~30 µm) or milligrams of aspirin (~6 mm) 9, 58 . Similarly, in spontaneously resolving peritonitis induced by the yeast cell-wall component zymosan, both resolvin E1 and protectin D1 activate and accelerate resolution 15 . Resolvins and protectins reduce neutrophil infiltration and increase non-phlogistic recruitment of monocytes. notably, resolvin E1, protectin D1 and an ATl analogue each display different kinetics and molecular profiles of action (TABLEs 1,2).
Organ-specific diseases. lipoxins are produced in the human gut mucosa 76 , where they limit persistent inflammation. As in the oral cavity, this is important given the continuous exposure of this organ to commensal bacteria. Patients with ulcerative colitis exhibit low to absent levels of lipoxin A 4 and have lower levels of mucosal 15-lipoxygenase 76 . interestingly, in the trinitrobenzene sulphonic acid (TnBS)-induced mouse model of Crohn's disease, oral administration of a lipoxin A 4 analogue has potent efficacy in promoting the resolution of colitis 77 . Resolvin E1 reduces colitis-associated mortality and protects animals from weight loss and shortening of the colonic mucosa 62 . Histological analysis of treated animals revealed fewer colonic ulcerations and reduced transmural infiltration of neutrophils, monocytes and lymphocytes. Serum levels of TnBS-specific igG were also decreased by this treatment, suggesting diminished antigen presentation and antibody production. Resolvin-E1-treated mice with colitis have reduced production of the pro-inflammatory cytokines TnF and il-12p40 and increased levels of inducible nitric oxide synthase and COX2, whereas the levels of interferon-γ, il-4 and il-10 remain essentially unchanged 62 . So, agonists of resolution of inflammation prevent immune-mediated tissue damage and restore tissue homeostasis. in Alzheimer's disease, soluble amyloid precursor protein-α, which stimulates in vitro proliferation of neural embryonic stem cells, activates neuroprotectin D1 biosynthesis. The hippocampal cornu ammonis region 1, but not the thalamus or occipital lobes, has decreased levels of DHA and neuroprotectin D1 (REF. 69 ). The hippocampus of individuals with Alzheimer's disease shows decreased expression of phospholipase A 2 and 15-lipoxygenase -key enzymes in neuroprotectin D1 biosynthesis in this tissue -hence it produces less of this endogenous protective mediator than healthy tissues 66, 69 . neuroprotectin D1 reduces the expression of pro-inflammatory genes and upregulates the expression of anti-apoptotic genes, thereby favouring the survival of brain cells 69, 70 .
Retinal pigment epithelium (RPE) of the eyes generates neuroprotectin D1 from endogenous DHA that protects them from oxidative-stress-induced apoptosis by limiting pro-inflammatory gene expression 70 . Photoreceptor-cell integrity depends on the RPE, and loss of integrity is characteristic of retinitis pigmentosa and age-related macular degeneration. RPE cells undergoing oxidative stress generate neuroprotectin D1, upregulate the expression of the anti-apoptotic proteins BCl-2 (B-cell lymphoma 2) and BCl-X l , and decrease the levels of pro-apoptotic proteins BAX (BCl-2-associated X protein) and BAD (BCl-2-antagonist of cell death). in addition, neuroprotectin D1 reduces leukocyte infiltration and pro-inflammatory gene expression in brain ischaemia-reperfusion injury 66, 69, 70 . independent of their neutrophil-directed actions, both lipoxin A 4 and protectin D1 also influence wound healing. The mouse cornea generates lipoxin A 4 and protectin D1 (REF. 78 ). in corneal thermal injury, topical application of either lipoxin A 4 or protectin D1 increases the rate of re-epithelialization by ~75%. The removal of corneal epithelial cells initiates neutrophil infiltration and increases the levels of the pro-inflammatory chemokine CXCl1 (murine equivalent of human il-8) produced by the corneal stroma. local treatment of lipoxin A 4 or protectin D1 decreased CXCl1 levels by ~60% (REF. 78 ).
Acute kidney injury is an inflammatory process in which repair and regeneration following acute inflammatory events can lead to interstitial fibrosis, scarring and chronic kidney failure with persistent leukocyte infiltration 79 . ischaemia followed by reperfusion leads to endogenous mobilization and increased levels of DHA in the blood and the production of D-series resolvins and protectins 80 . When treated with resolvins before bilateral renal ischaemia, mouse kidneys were protected from injury; the serum levels of creatinine were lower in treated mice compared with control mice. Protectin D1 was also protective, and both protectin D1 and resolvins reduced the number of tissue neutrophils and limited the deposition of interstitial collagen, thereby protecting the mice against tissue fibrosis. Resolvin D1 when given after ischaemic kidney injury protected mice from acute renal failure; however, this was not the case with protectin D1. These results suggest that D-series resolvins and protectin D1 activate resolution circuits in acute kidney injury 80 . Dietary incorporation of DHA is protective against mouse liver necro-inflammatory injury through increased local production of DHA-derived mediators 81 . Hepatocytes incubated with DHA or 17-HDHA show less hydrogen-peroxide-induced DnA damage and less cellular oxidative stress. mice fed a DHA-enriched diet are protected from carbon-tetrachloride-induced necroinflammatory hepatic damage 81 . in the lungs, lipoxins generated in mouse models of asthma are potent regulators of airway inflammation and hyper-responsiveness 82 . lipoxins and their stable analogues reduce pulmonary inflammation by decreasing neutrophil, eosinophil and lymphocyte recruitment and activation. They also block oedema formation and reduce the levels of pro-inflammatory mediators il-5, il-13, CCl11, prostanoids and cysteinyl leukotriene 82 . Consistent with this key counter-regulatory role, individuals with severe asthma have apparent defects in lipoxin biosynthesis 83 . Protectin D1 is present, albeit at reduced levels in asthmatic subjects and potentially reduces both airway inflammation and hyper-reactivity 84 . Therefore, it appears that pro-resolution lipid mediators have roles in both physiological and pathophysiological processes in specific tissues.
Concluding remarks and future directions
The recently identified resolvin and protectin families and the lipoxin class of eicosanoids constitute a new genus of pro-resolution mediators with dual actions. Their discovery opens new avenues for the development of treatment strategies for inflammatory diseases and the development of resolution-based pharmacology and lipidomics-based therapeutics.
As many current and widely used drugs were developed without knowledge of their impact in resolution processes, some agents, such as selective COX2 inhibitors and certain lipoxygenase inhibitors, have now been shown to impair the tissue programmes of resolution, thereby delaying the return to homeostasis 5, 15, 85 , whereas others, such as glucocorticoids 86 , aspirin 87 , cyclin-dependent kinase inhibitors 88 and statins 52 , seem to work in concert with endogenous pro-resolution processes. COX inhibitors reduce the amplitude of and the cardinal signs of inflammation by inhibiting prostanoid biosynthesis. Therefore, combining pro-resolution molecules with lipoxygenase or COX pathway antagonists may be a useful strategy to restore resolution and control excessive inflammation. Pro-resolution mediators may also have therapeutic potential in settings in which sustained inflammation and impaired resolution are components of disease pathophysiology (TABLE 2) . indeed, susceptibility to chronic inflammatory disorders may arise from defects in the lipid-mediator receptors and/or their signalling pathways, or from defects in the de novo biosynthesis of pro-resolution molecules 84, 89 . nevertheless, before resolution pathways can be harnessed for the treatment of human diseases, several important questions need to be addressed: will it be possible to treat organ-specific inflammatory disorders with different pro-resolution mediators and/or their analogue mimetics in a tissue-specific manner? Will dietary supplementation with intermediates and/or precursors be beneficial for the local production of pro-resolution mediators? Will knowledge of these new pathways lead to an increased appreciation of potential deleterious effects of excessive DHA and EPA intake that could lead to increases in auto-oxidation of these fatty acids that can damage cells and tissues? Finally, given that lipoxins, resolvin E1 and protectins act on T cells, dendritic cells and phagocytic cells, might nutrition represent a molecular link between the innate and adaptive immune systems?
The relationship between essential fatty acids in nutrition, dietary supplementation and the biosynthesis of resolvins and protectins is an area of active research. in this regard, our studies with Kang and colleagues of mice that overexpress fatty acid desaturase from Caenorhabditis elegans (fat-1-transgenic mice) help to address discrepancies in dietary studies that can arise from individual genetic and feeding variations. The fat-1-transgenic mice produce and store higher levels of EPA and DHA in their tissues than wild-type mice and as a result generate increased levels of resolvins and protectins. After challenge, fat-1-transgenic mice show reduced gastrointestinal inflammation 90 and less tumour metastasis 91 . Whether these exciting findings extend to humans will be of interest in further studies. 
